Neovacs (Alternext: ALNEV), a spin-off from the Université Pierre & Marie Curie in Paris, is a biotechnology company focused on an active immunotherapy technology platform, with applications for auto-immune diseases and other chronic diseases. It was founded by Professor Daniel Zagury, MD, PhD, one of the best immunologists in the world.
Neovacs was listed on Alternext in April 2010. It was the first successful listing on the stock market in the French biotechnology sector since 2008. Truffle Capital sold its participation in Neovacs in 2015